Working… Menu

Adjuvant Avelumab in Merkel Cell Cancer (ADAM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03271372
Recruitment Status : Recruiting
First Posted : September 5, 2017
Last Update Posted : May 27, 2021
National Cancer Institute (NCI)
EMD Serono
Information provided by (Responsible Party):
University of Washington

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 25, 2025
Estimated Study Completion Date : February 25, 2025